UKCA conformity assessment for medical devices: approved bodies, procedures and costs

1. Key takeaways

The long-term recognition decision of 21 October 2026 did not abolish UKCA: the official announcement states expressly that the UKCA route continues to operate as the domestic approval pathway for Great Britain and is being modernised through the proposed premarket statutory instrument. UKCA retains real, present value for two groups of companies. The first holds products with no CE certificate at all, for example innovative devices approved only by the FDA or the TGA, which currently have no transitional basis to enter Great Britain. The second runs product lines launched in the United Kingdom first, with no near-term plan to enter the European Union, for which a CE certificate would be an unused asset.

For everyone else, UKCA has become an option to be priced rather than an obligation to be scheduled. That reframing changes the conversation with management: the question is no longer when to book the conformity assessment but whether the British market justifies one at all, and the answer depends on market size, competitive timing and the certificate portfolio the company already holds on the European side.

It is worth stating the negative case as clearly as the positive one. For a product that already holds an MDR certificate and sells in the European Union, a UKCA certificate currently adds a second assessment of substantially the same evidence, a second annual surveillance cycle, and a second set of fees, in exchange for access to a market that indefinite recognition now keeps open on the CE basis. Unless the British market is strategically significant, or the company wants insulation from future EU-side disruption, the arithmetic rarely supports duplicating the assessment today. The decision should be documented either way, so that it can be reopened cheaply when the premarket statutory instrument changes the picture.

2. Legal basis

• UK MDR 2002 (SI 2002/618, as amended): regs 13, 27 and 40 (procedures for affixing the British marking); regs 17, 30 and 41 (manufacturers and conformity assessment procedures); regs 18, 31 and 42 (UK approved bodies and conformity assessment procedures); Part V regs 44A, A45, 45, 46, 47 and 47A (designation, selection and register of conformity assessment bodies).
• GOV.UK official list titled ‘List of UK approved bodies for medical devices’; MHRA guidance titled ‘Medical devices: list of UK approved bodies’.
• GOV.UK / MHRA news announcement (21 October 2026): the UKCA route continues to operate and is being modernised.

3. Expert insights

Insight one: the cost structure of UKCA differs from CE. For higher-risk categories, UKCA requires assessment by a UK approved body. The number of designated bodies is limited, and their assessment scheduling and fees are the main variables in any project plan. The official British list carries each body’s designation number, contact details, designation scope and validity period, and before selecting a body the scope must be checked item by item against the product. A body may be designated for active implantables but not for the IVD class your product sits in, and a scope gap discovered after contracting means lost months and re-negotiation.

Insight two: conformity assessment procedures are set out by part and by class. Reg 17 (general devices), reg 30 (active implantable devices) and reg 41 (IVDs) each set out the procedures a manufacturer may choose; regs 18, 31 and 42 correspondingly set out the duties of the approved bodies. The annex system, as amended by Schedule 2A, provides the specific modules. Reading the three regulation pairs side by side, with the annexes open, is the reliable way to map a product to its permissible procedure set, and the mapping should be recorded because it determines the technical documentation structure the body will expect.

Insight three: UKCA links directly to labelling obligations. Once UKCA is affixed, the name and address of the UKRP must appear on the label, the outer packaging or the instructions for use; where a UK approved body is involved, its designation number must appear adjacent to the UKCA mark. This means a UKCA decision triggers label redesign costs, artwork change control and stock run-out management, all of which must be included in the investment calculation. Companies that budget only the assessment fee systematically understate the true cost of the route by the entire labelling and inventory workstream.

One further practical point concerns the sequencing of the UKRP appointment. Since the UKRP’s details must appear once UKCA is affixed, the appointment agreement should be signed, and the details settled, before artwork is finalised, so that the label text does not have to be reopened after the assessment has already cost time and money. Folding the UKRP decision into the UKCA project plan as a predecessor task, rather than leaving it to the registration phase, removes a small but recurring source of rework in British entry projects.

4. Practical recommendations

GRZAN recommends driving every UKCA decision through a three-question decision tree: does the product already hold CE, does it have an EU launch plan, and is it a United Kingdom first? Only products answering no-to-CE and yes-to-UK-value should proceed. For projects that decide to invest in UKCA, the correct sequencing is to confirm the designation scope and the assessment schedule with candidate UK approved bodies first, and only then to build the project timetable backwards from the confirmed slot, which avoids the expensive rework that follows when a chosen body turns out not to cover the product’s scope.

The comparison should be documented as a short written record per product line: the UKCA cost estimate, the CE-based alternative, the expected British revenue window for each, and the label change implications. That record keeps the decision auditable, allows it to be revisited cheaply when the implementing legislation lands, and prevents the drift back into UKCA-by-default thinking once internal pressure to show progress returns.

5. Verification checklist

• □ The designation scope of the selected UK approved body covers this product
• □ The validity of that designation covers the project period
• □ Label redesign and the cost of adding UKRP information to the label have been estimated
• □ The applicable conformity assessment procedure has been confirmed (reg 17 / 30 / 41)
• □ An input-output comparison of the UKCA and CE dual tracks has been completed

Regulatory information verified as of 29 October 2026.

• Appointment of a UK responsible person (UKRP) and support for signing the letter of authorisation
• MHRA registration (DORS): end-to-end filing and account lifecycle management
• Device classification, GMDN code selection and annual registration fee estimates
• Dual-route design for Great Britain and Northern Ireland, including UK(NI) options
• Post-market surveillance (PMS) system build, PMSR/PSUR preparation and vigilance reporting
• Emergency handling of serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory change and compliance gap assessments

GRZAN supports manufacturers entering the United Kingdom with UKCA registration pathways and classification strategy, from first route analysis through to registration and post-market obligations. For a structured review of your product portfolio, contact info@grzanglobal.com.